 |
 |
 |
 |
 |
 |
|
||||||
|
SELECT PUBLICATIONS
Almhanna K et al. Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: A case series. Anticancer Drugs 2008;19(2):217-9. Abstract
Berry S et al. Lack of effect of starting bevacizumab shortly after venous access implantation on wound healing/bleeding complications: Preliminary results from first BEAT. Proc ASCO GI 2006; Abstract 245.
Cho BC et al. Phase II study of erlotinib in advanced non-small cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25(18):2528-33. Abstract
Cohen MH et al. FDA drug approval summary: Bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12(6):713-8. Abstract
Eaby B et al. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clinical Journal of Oncology Nursing 2008;12(2): 283-90. Abstract
Engelman JA et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316(5827):1039-43. Abstract
Fish-Steagall A et al. Clinical experience with anti-EGFR therapy. Semin Oncol Nurs 2006;22(1 Suppl 1):10-9. Abstract
Fox SW, Lyon DE. Symptom clusters and quality of life in survivors of lung cancer. Oncology Nursing Forum 2006;33(5): 931-6. Abstract
Gatzemeier U et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25(12):1545-52. Abstract
Gobel BH. Nursing considerations of bevacizumab use in multiple tumor types. Oncology Nursing Forum 2007;34(3): 693-701. Abstract
Greco A et al. Albumin bound paclitaxel wkly + carboplatin: First-line therapy for advanced NSCLC. Proc Chemotherapy Foundation Symposium XXIV 2006. No abstract available
Hansen F, Sawatzky JV. Stress in patients with lung cancer; A human response to illness. Oncology Nursing Forum 2008;35(2): 217-23. Abstract
Hawkins MJ et al. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2007; Abstract 7659.
Herbst RS et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25(30):4743-50. Abstract
Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non small-cell lung cancer. J Clin Oncol 2005;23(11):2544-55. Abstract
Heymach JV et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Proc ASCO 2006; Abstract 7016.
Hirsch FR et al. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. Proc ASCO 2006; Abstract 7072.
Hoffman AJ et al. Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer. Oncology Nursing Forum 2007;34(4):785-92. Abstract
Jackman DM et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24(27):4517-20. Abstract
Johnson DH et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11): 2184-91. Abstract
Khoukaz T. Administration of anti-EGFR therapy: A practical review. Semin Oncol Nurs 2006;22(1 Suppl 1):20-7. Abstract
Lacouture ME et al. Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park) 2007;21(11 Suppl 5):17-21. Abstract
Lynch TJ Jr et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 2007;12(5):610-21. Abstract
Manegold C et al. Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Proc ASCO 2007; Abstract LBA7514.
Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs 2006;22(3):152-62. Abstract
Nagrath S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20;450(7173):1235-9. Abstract
Natale RB et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. Proc ASCO 2006; Abstract 7000.
Oishi K. Clinical approaches to minimize rash associated with EGFR inhibitors. Oncology Nursing Forum 2008;35(1):103-11. Abstract
Paez JG et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304(5676): 1497-500. Abstract
Reynolds C et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). Proc ASCO 2007; Abstract 7610.
Riely GJ et al. A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer. Proc ASCO 2007; Abstract 7619
Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24): 2542-50. Abstract
Seek AJ, Hogle WP. Modeling a better way: Navigating the healthcare system for patients with lung cancer. Clinical Journal of Oncology Nursing 2007;11(1):81-5. Abstract
Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007;12(3):325-30. Abstract
Sipples R. Common side effects of anti-EGFR therapy: Acneform rash. Semin Oncol Nurs 2006;22(1 Suppl 1):28-34. Abstract
Sugrue MM et al. Serious wound healing complications (WHCs) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE Observational Cohort Study. Gastrointestinal Cancers Symposium 2008;Abstract 450.
Tsao MS et al. Erlotinib in lung cancer — Molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44. Abstract
Tyson LB. Non-small cell lung cancer: New hope for a chronic illness. Oncology Nursing Forum 2007;34(5):963-70. Abstract
Wakelee HA et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25(5):472-8. Abstract
William WN Jr et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). Proc ASCO 2007;Abstract 18098.
| Table of Contents | Top of Page |
